Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Chester Poon"'
Autor:
Simon Mantha, Subrata Chatterjee, Rohan Singh, John Cadley, Chester Poon, Avijit Chatterjee, Daniel Kelly, Michelle Sterpi, Gerald Soff, Jeffrey Zwicker, José Soria, Magdalena Ruiz, Andres Muñoz, Maria Arcila
Venous thromboembolism (VTE) is a common and impactful complication of cancer. Several clinical prediction rules have been devised to estimate the risk of a thrombotic event in this patient population, however they are associated with limitations. We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b6f6f597ae5c7cdc0e78bb4f948d0f23
https://doi.org/10.21203/rs.3.rs-2870367/v1
https://doi.org/10.21203/rs.3.rs-2870367/v1
Autor:
Jibran, Majeed, Barbara S, Turner, Deirdre, Kelly, Chester, Poon, Julie A, Thompson, John, Barrett, Gerald A, Soff
Publikováno v:
Journal of the Advanced Practitioner in Oncology. 13:382-391
Background: Cancer patients with venous thromboembolic (VTE) disease are complex, and many factors must be considered when initiating anticoagulation management. Clinical decision support systems can aid in decision-making by utilizing guidelines at
Autor:
Margaret B. Nolan, Thomas M. Piasecki, Stevens S. Smith, Timothy B. Baker, Michael C. Fiore, Robert T. Adsit, Daniel M. Bolt, Karen L. Conner, Steven L. Bernstein, Oliver D. Eng, David Lazuk, Alec Gonzalez, Todd Hayes-Birchler, Douglas E. Jorenby, Heather D'Angelo, Julie A. Kirsch, Brian S. Williams, Sean Kent, Hanna Kim, Stanley A. Lubanski, Menggang Yu, Youmi Suk, Yuxin Cai, Nitu Kashyap, Jomol Mathew, Gabriel McMahan, Betsy Rolland, Hilary A. Tindle, Graham W. Warren, Noor Abu-el-rub, Lawrence C. An, Andrew D. Boyd, Darlene H. Brunzell, Victor A. Carrillo, Li-Shiun Chen, James M. Davis, Vikrant G. Deshmukh, Deepika Dilip, Adam O. Goldstein, Patrick K. Ha, Eduardo Iturrate, Thulasee Jose, Niharika Khanna, Andrea King, Elizabeth Klass, Michelle Lui, Robin J. Mermelstein, Chester Poon, Elisa Tong, Karen M. Wilson, Wendy E. Theobald, Wendy S. Slutske
Publikováno v:
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, vol 32, iss 1
Background: There is mixed evidence about the relations of current versus past cancer with severe COVID-19 outcomes and how they vary by patient and cancer characteristics. Methods: Electronic health record data of 104,590 adult hospitalized patients
Autor:
Elizabeth V. Robilotti, Karissa Whiting, Anabella Lucca, Chester Poon, Krupa Jani, Tracy McMillen, Scott Freeswick, Deborah Korenstein, N. Esther Babady, Venkatraman E. Seshan, Mini Kamboj
Publikováno v:
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. 28(12)
To describe effectiveness of mRNA vaccines by comparing 2-dose (2D) and 3-dose (3D) healthcare worker (HCW) recipients in the setting of Omicron variant dominance. Performance of 2D and 3D vaccine series against SARS-CoV-2 variants and the clinical o
Autor:
Tobias M. Hohl, Chester Poon, N. Esther Babady, Michael Lässig, Deborah Korenstein, Karissa Whiting, Benjamin D. Greenbaum, Tracy McMillen, Denis Ruchnewitz, Suzanne Kelson, Krupa Jani, Kevin P. Browne, Alexander Solovyov, Rebecca S. Guest, Scott Freeswick, Anabella Lucca, Venkatraman E. Seshan, Elizabeth Robilotti, Marta Łuksza, Mini Kamboj
Publikováno v:
Clin Infect Dis
Background Vaccine-induced clinical protection against severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) variants is an evolving target. There are limited genomic level data on SARS CoV-2 breakthrough infections and vaccine effectiveness (
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2e4ed37aea4299b57bfc05bb01571c42
https://europepmc.org/articles/PMC9612794/
https://europepmc.org/articles/PMC9612794/
Autor:
Simon Mantha, Chester Poon, Gerald A. Soff, Alok A. Khorana, Claire M Sathe, Leah Gilbert, Debra M. Sarasohn
Publikováno v:
Blood. 136:18-19
Introduction: The Khorana Score (KS) is a validated tool to assess the risk of thrombosis in cancer patients, prior to initiation of chemotherapy. The AVERT and CASSINI studies evaluated prophylactic anticoagulation with apixaban or rivaroxaban for p